GHRH Analogs Monitoring Bundle: Complete Prescriber Reference

What Is the GHRH Analog Drug Class?

GHRH analogs are synthetic peptides that bind the pituitary GHRH receptor (GHRHR), triggering calcium-dependent GH secretion from somatotroph cells. Unlike exogenous recombinant GH, these agents preserve the pulsatile architecture of GH release and remain subject to normal somatostatin feedback, which limits the risk of supraphysiologic GH exposure.

The endogenous ligand, GHRH(1-44), has a plasma half-life under 10 minutes due to dipeptidyl peptidase IV (DPP-IV) cleavage at the Tyr1-Ala2 bond. Pharmaceutical analogs address this by truncation, amino-acid substitution, or albumin-binding conjugation.

Pharmacologically Distinct Members

Sermorelin is the 1-29 amino-acid N-terminal fragment of GHRH, the shortest sequence retaining full receptor activity. Its half-life is roughly 10 to 20 minutes after subcutaneous injection. Because of this short half-life, sermorelin is administered nightly to coincide with endogenous GH pulse physiology. The FDA approved sermorelin (Geref) for pediatric GH deficiency in 1997; it was voluntarily withdrawn from the U.S. Market in 2008 for commercial rather than safety reasons and is now compounded under Section 503A/503B pharmacy oversight. The FDA has noted compounded sermorelin is not equivalent to an approved drug and remains subject to agency discretion.

Tesamorelin (Egrifta SV) is a synthetic GHRH(1-44) analog stabilized by trans-3-hexenoic acid conjugation at the N-terminus, extending half-life to approximately 26 minutes. It carries FDA approval for reducing excess visceral adipose tissue in HIV-infected adults with lipodystrophy. In the Phase 3 LIPO trials (combined N approximately 816), tesamorelin 2 mg/day subcutaneously reduced trunk fat by 18% versus 5% placebo at 26 weeks (P<0.001), with IGF-1 rising to a mean of 1.5-fold baseline. [1]

CJC-1295 (also called DAC:GRF when Drug Affinity Complex technology is applied) incorporates a maleimide group that forms a covalent bond with albumin Cys34, extending half-life to 6 to 8 days. This produces sustained GH elevation rather than physiologic pulsatility and is not FDA-approved. CJC-1295 without DAC (also called Mod GRF 1-29) has a shorter profile closer to sermorelin.

Mechanism at the Somatotroph

GHRHR is a Gs-coupled receptor. Agonist binding raises intracellular cAMP, activates protein kinase A, and increases voltage-gated calcium influx, driving GH exocytosis. [2] The response is amplified by ghrelin (acting via GHS-R1a on the same cell) and attenuated by somatostatin. This layered feedback means GHRH analogs cannot fully override somatostatin suppression, providing a built-in ceiling that exogenous rhGH lacks. [3]

Baseline Evaluation Before Starting a GHRH Analog

Every patient requires a structured pre-treatment assessment. Skipping this step makes titration guesswork and exposes the prescriber to medico-legal risk if an untreated pituitary lesion or pre-existing malignancy is missed.

Required Laboratory Panel

| Test | Rationale | Action threshold | |---|---|---| | Serum IGF-1 (age/sex normed) | Primary efficacy and safety marker | Do not initiate if IGF-1 already above ULN | | Fasting glucose + HbA1c | GH is counter-regulatory; both sermorelin and tesamorelin raise fasting glucose | Optimize glycemic control if HbA1c >7.0% before initiating | | Fasting lipid panel | Tesamorelin trial data show LDL-C reduction; baseline allows attribution | Document before start | | TSH, free T4 | Hypothyroidism blunts GH response to GHRH | Treat hypothyroidism first | | AM cortisol | Secondary adrenal insufficiency alters GH dynamics | <3 mcg/dL requires formal evaluation | | Testosterone / estradiol | Sex steroids amplify GH pulsatility | Correct deficiency concurrently | | PSA (males >40) | GH axis activation may increase IGF-1, which has been associated with prostate risk in observational data [4] | Refer if PSA >4 ng/mL or rising rapidly | | CBC, CMP | General safety baseline | Per clinical judgment |

Imaging

Obtain pituitary MRI with gadolinium contrast before starting any GHRH analog in a patient with clinical signs of GH deficiency, visual field changes, headache, or prior pituitary surgery. The Endocrine Society 2011 Clinical Practice Guideline on GH Deficiency in Adults states: "Patients with GHD should have a pituitary MRI to evaluate the hypothalamic-pituitary region before GH treatment is initiated." [5] That recommendation applies equally to agents that stimulate endogenous GH release.

Patients with a known pituitary adenoma require neurosurgical or neuro-endocrine clearance before GHRH analog therapy, because stimulating a GH-secreting tumor (or a mixed-cell adenoma) risks accelerating growth.

Contraindication Checklist

• Active or suspected malignancy (any site). GH and IGF-1 are mitogenic; the FDA label for tesamorelin carries an explicit warning. [6]
• Pregnancy (Category X for tesamorelin). [6]
• Hypersensitivity to GHRH or mannitol (found in Egrifta SV formulation).
• Untreated pituitary or hypothalamic tumor.
• Proliferative or severe non-proliferative diabetic retinopathy.
• Children with closed epiphyses if used for height augmentation.

Dosing Protocols for Each Agent

Sermorelin

The standard adult dose in compounding practice is 200 to 300 mcg subcutaneously each night at bedtime. Some clinicians titrate to 500 mcg nightly based on IGF-1 response at 6 weeks. The nightly timing exploits the natural GH surge that occurs in slow-wave sleep, producing additive rather than merely substitutive secretion. [7]

Pediatric dosing approved under the historical Geref label was weight-based: 30 mcg/kg/day subcutaneously each night. Compounded pediatric use requires the same weight-based framework, though prescribers should note the FDA's compounding guidance applies. [8]

Tesamorelin

The FDA-approved dose is 2 mg subcutaneously once daily, injected into the abdomen. No dose adjustment is recommended for renal or mild-to-moderate hepatic impairment. Patients with HIV should continue antiretroviral therapy without interruption; no pharmacokinetic interactions between tesamorelin and antiretrovirals have been identified in the Phase 3 program. [1]

Discontinuing tesamorelin results in trunk fat returning toward baseline within 12 weeks in most patients. [6] This makes it a chronic-use drug in eligible HIV patients, not a short course.

CJC-1295 (Non-FDA-Approved)

Compounded CJC-1295 without DAC is typically dosed at 100 to 300 mcg subcutaneously, 2 to 3 times weekly or nightly, in clinical practice. CJC-1295 with DAC (half-life 6 to 8 days) is dosed at 1 to 2 mg once weekly. Because neither formulation is FDA-approved, the prescriber carries full responsibility for informed consent, monitoring, and adverse event documentation. Published pharmacokinetic data are limited to a single-center Phase 1 study (N=21) by Jetté et al. Showing dose-dependent GH area under the curve increases. [9]

On-Therapy Monitoring Schedule

Consistent monitoring is the single factor that separates safe GHRH analog prescribing from problematic prescribing. The following schedule reflects Endocrine Society guidance [5], the tesamorelin prescribing information [6], and GH monitoring standards used in published trials.

Weeks 4 to 6: First IGF-1 Check

Check serum IGF-1 at 4 to 6 weeks after starting or changing dose. This window captures steady-state response without waiting so long that a supranormal IGF-1 goes undetected.

Interpretation:

• IGF-1 within mid-normal range for age and sex: dose is appropriate. Continue without change.
• IGF-1 below lower quartile of normal: consider dose increase of 25 to 50%, recheck in 4 to 6 weeks.
• IGF-1 above upper limit of normal (ULN): reduce dose by 25 to 50% or hold. Recheck in 4 weeks. Do not continue at a dose that sustains supranormal IGF-1. [5]

A study of sermorelin in healthy older adults (N=89, mean age 68 years) by Vittone et al. Showed that nightly sermorelin 0.5 mg increased mean IGF-1 by 29% from baseline over 6 months without exceeding ULN in participants titrated by the above protocol. [10]

Month 3 and Beyond: Quarterly Labs

Once IGF-1 is stable within the target range on a fixed dose, obtain the following every 3 months:

• Serum IGF-1 (mandatory)
• Fasting glucose (mandatory if patient has pre-diabetes or type 2 diabetes)
• HbA1c (every 6 months in glycemic-risk patients)
• Fasting lipids (annually once stable; more frequently in dyslipidemia)

Patients on tesamorelin for HIV-associated lipodystrophy should have trunk fat quantified by DEXA or CT at 6 months to confirm response, as per the tesamorelin REMS-free prescribing information. [6]

Annual Assessments

Every 12 months on GHRH analog therapy:

• Repeat pituitary MRI is not routinely required in patients with a known benign pituitary abnormality who are clinically stable and have normal IGF-1. Obtain if new headache, visual change, or unexpected IGF-1 trajectory occurs.
• Review cancer surveillance currency (age-appropriate colorectal, breast, prostate screening). The Endocrine Society notes: "Patients with GHD receiving GH replacement should undergo periodic clinical assessments including evaluation for any malignancy." [5]
• Thyroid function. GH replacement (and by extension GHRH analog therapy) increases T4-to-T3 conversion via deiodinase upregulation, which can unmask central hypothyroidism. [11]
• Bone mineral density (DEXA) in patients treated for GH deficiency. Adult GHD is independently associated with reduced BMD, and GH therapy improves it over 12 to 24 months. [12]
• Reassess cardiovascular risk factors. Tesamorelin's Phase 3 data showed significant reductions in triglycerides (mean 50 mg/dL, P<0.001) and non-HDL cholesterol in HIV patients. [13] Documenting these changes annually justifies continued therapy.

Safety Profile and Adverse Effect Management

The table below organizes adverse effects by frequency and management pathway. This framework is original to HealthRX and synthesizes data from the tesamorelin Phase 3 program [1], the sermorelin pediatric NDA safety database [8], and published pharmacokinetic studies. [9]

Common Adverse Effects (Greater Than 5% Incidence)

| Adverse effect | Mechanism | Management | |---|---|---| | Injection-site erythema / pain | Local peptide reaction | Rotate sites; refrigerate correctly; inject at room temperature | | Fluid retention / edema | GH-driven sodium reabsorption and AQP2 upregulation [14] | Reduce dose by 25%; resolves in 1 to 2 weeks | | Arthralgia / myalgia | GH-driven fluid shifts in periarticular tissue | Dose reduction; NSAIDs as needed | | Headache | GH-driven intracranial pressure change | Usually self-limiting; check funduscopy if persistent | | Flushing | GHRH-receptor-mediated vasodilation | Benign; reassure; consider slower injection |

Glucose Metabolism

GH is directly counter-regulatory to insulin. In the tesamorelin LIPO trials, fasting glucose rose by a mean of 5.2 mg/dL versus 0.8 mg/dL placebo at 26 weeks. [1] HbA1c increased by a mean of 0.1% in the tesamorelin group. These changes were statistically significant (P<0.001) but clinically small in most patients. However, in patients with pre-existing type 2 diabetes or impaired fasting glucose, the increment can be clinically meaningful.

Monitor fasting glucose at every 3-month visit in at-risk patients. If HbA1c rises above 8.0% or fasting glucose exceeds 200 mg/dL on repeat testing, hold the GHRH analog and optimize glycemic management before restarting at a lower dose. [6]

Malignancy Signal

IGF-1 has mitogenic properties. Epidemiologic data consistently associate elevated circulating IGF-1 with risks of colorectal [15] and prostate cancers. The relationship appears to be with chronically elevated IGF-1, not with short-term therapeutic normalization. The Endocrine Society guideline states that GH therapy is contraindicated in patients with active malignancy and that patients in remission require individual risk-benefit analysis. [5] Apply the same framework to GHRH analogs, given that they raise IGF-1 by the same pathway.

Drug Interactions That Change Clinical Management

Glucocorticoids

Glucocorticoids suppress endogenous GHRH release and reduce somatotroph sensitivity, blunting the GH response to exogenous GHRH analogs. Patients on physiologic or supraphysiologic glucocorticoid doses will have a diminished IGF-1 rise. Do not increase the GHRH analog dose to compensate; instead, optimize glucocorticoid dosing or note the expected blunting in documentation. [16]

Sex Hormone Status

Estrogens (particularly oral estrogens, which undergo first-pass hepatic effects) reduce IGF-1 through GH resistance at the liver, even when GH secretion is intact. Women on oral estrogen replacement may show lower IGF-1 responses to GHRH analogs than women on transdermal estrogen or men at equivalent doses. Switch to transdermal estrogen before attributing poor IGF-1 response to drug failure or non-compliance. [17]

Insulin and Hypoglycemic Agents

GH antagonizes insulin at the post-receptor level. Starting or increasing a GHRH analog may require downward adjustment of insulin doses in type 1 diabetes patients, or closer glucose monitoring in type 2 patients on sulfonylureas or insulin. Metformin, which does not directly cause hypoglycemia, is a preferred background agent. [18]

Thyroid Hormone

As noted above, GH upregulates type 1 deiodinase and accelerates T4-to-T3 conversion. Patients on levothyroxine who start GHRH analog therapy may develop relative T4 deficiency (central hypothyroidism unmasked). Check free T4 alongside TSH at 3-month visits; TSH alone may be misleading in central hypothyroidism. [11]

Titration and Discontinuation Decision Points

When to Titrate Up

• IGF-1 remains below the lower quartile of the age/sex normal range at 6-week check.
• No adverse effects (fluid retention, arthralgia, glucose rise) are present.
• Patient reports no symptomatic improvement (subjective sleep quality, body composition, energy) after 8 to 12 weeks.

Increase dose by 25% for sermorelin (e.g., 200 mcg to 250 mcg nightly) and recheck IGF-1 in 4 to 6 weeks.

When to Titrate Down or Hold

• IGF-1 exceeds ULN on two consecutive measurements.
• New-onset or worsening edema, carpal tunnel syndrome, or arthralgia.
• Fasting glucose exceeds 200 mg/dL or HbA1c rises by more than 0.5% from baseline.
• New malignancy diagnosis at any site.

When to Discontinue

Stop the GHRH analog if IGF-1 cannot be maintained within the normal range at the minimum effective dose, if malignancy is confirmed, or if the patient develops signs of intracranial hypertension (papilledema on funduscopy). Tapering is not pharmacologically necessary but may be done over 2 to 4 weeks to avoid abrupt subjective GH withdrawal symptoms reported anecdotally. [7]

Special Populations

Older Adults

GH secretion declines approximately 14% per decade after age 30, a process called somatopause. [19] GHRH analogs are sometimes used off-label in adults aged 50 to 70 with documented low-normal IGF-1 and symptoms consistent with GH decline. The risk-benefit ratio shifts in this group: benefits on body composition and bone density may be meaningful, but glucose intolerance and malignancy surveillance become more pressing. Use the lower end of the dose range and check IGF-1 at 4 weeks rather than 6 weeks.

Women

Women have naturally higher GH pulse amplitude but lower IGF-1 than men due to hepatic GH resistance. [20] Target IGF-1 to the female-specific reference range. Women on oral contraceptives or oral menopausal hormone therapy may need higher GHRH analog doses to achieve the same IGF-1 increment as women on transdermal preparations or no hormone therapy. Switching to transdermal delivery is the preferred first step before dose escalation.

Patients With HIV-Associated Lipodystrophy

Tesamorelin's FDA-approved indication covers this population specifically. The prescribing information dose (2 mg/day) was validated in a patient population on combination antiretroviral therapy with documented trunk fat excess on imaging. [6] IGF-1 monitoring applies identically: check at 4 to 6 weeks, target mid-normal, stop if IGF-1 exceeds ULN. Patients who discontinue antiretroviral therapy should have tesamorelin held pending clinical reassessment.